PD Therapeutic Approaches Scorecard

Migration, Crosslink

📖

PD Therapeutic Approaches Scorecard

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-pd-therapeutic-scoreca

📖 Wiki Page

therapeutic2591 wordssynced 2026-04-02

PD Therapeutic Approaches Scorecard

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">PD Therapeutic Approaches Scorecard</th>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>Do we understand HOW this works at molecular level?</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>Phase 1/2/3 trial data, epidemiological support</td>
</tr>
<tr>
<td class="label">Delivery Feasibility</td>
<td>Can we get this to the brain at therapeutic doses?</td>
</tr>
<tr>
<td class="label">Safety Profile</td>
<td>Side effects, long-term toxicity, surgical risks</td>
</tr>
<tr>
<td class="label">Combinability</td>
<td>Can this pair with other approaches synergistically?</td>
</tr>
<tr>
<td class="label">Timeline to Impact</td>
<td>How soon could patients benefit?</td>
</tr>
<tr>
<td class="label">Addresses Root Cause</td>
<td>Does this fix upstream pathology or just symptoms?</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">1</td>
<td>Levodopa/Carbidopa</td>
</tr>
<tr>
<td class="label">2</td>
<td>Exercise/Lifestyle interventions</td>
</tr>
<tr>
<td class="label">3</td>
<td>MAO-B inhibitors (rasagiline, safinamide)</td>
</tr>
<tr>
<td class="label">4</td>
<td>[GLP-1 receptor](/entities/glp1-receptor) agonists</td>
</tr>
<tr>

...

PD Therapeutic Approaches Scorecard

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">PD Therapeutic Approaches Scorecard</th>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>Do we understand HOW this works at molecular level?</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>Phase 1/2/3 trial data, epidemiological support</td>
</tr>
<tr>
<td class="label">Delivery Feasibility</td>
<td>Can we get this to the brain at therapeutic doses?</td>
</tr>
<tr>
<td class="label">Safety Profile</td>
<td>Side effects, long-term toxicity, surgical risks</td>
</tr>
<tr>
<td class="label">Combinability</td>
<td>Can this pair with other approaches synergistically?</td>
</tr>
<tr>
<td class="label">Timeline to Impact</td>
<td>How soon could patients benefit?</td>
</tr>
<tr>
<td class="label">Addresses Root Cause</td>
<td>Does this fix upstream pathology or just symptoms?</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">1</td>
<td>Levodopa/Carbidopa</td>
</tr>
<tr>
<td class="label">2</td>
<td>Exercise/Lifestyle interventions</td>
</tr>
<tr>
<td class="label">3</td>
<td>MAO-B inhibitors (rasagiline, safinamide)</td>
</tr>
<tr>
<td class="label">4</td>
<td>[GLP-1 receptor](/entities/glp1-receptor) agonists</td>
</tr>
<tr>
<td class="label">5</td>
<td>[Alpha-synuclein](/proteins/alpha-synuclein) antibodies (prasinezumab)</td>
</tr>
<tr>
<td class="label">6</td>
<td>Deep Brain Stimulation</td>
</tr>
<tr>
<td class="label">7</td>
<td>LRRK2 inhibitors (dNL-1, BIIB122)</td>
</tr>
<tr>
<td class="label">8</td>
<td>Dopamine agonists</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">9</td>
<td>GBA chaperones (ambroxol)</td>
</tr>
<tr>
<td class="label">10</td>
<td>Gene therapy (AAV-GAD, AAV-AADC)</td>
</tr>
<tr>
<td class="label">11</td>
<td>COMT inhibitors (opicapone)</td>
</tr>
<tr>
<td class="label">12</td>
<td>Alpha-synuclein aggregation inhibitors</td>
</tr>
<tr>
<td class="label">13</td>
<td>[Tau](/proteins/tau)-targeted therapies</td>
</tr>
<tr>
<td class="label">14</td>
<td>Apomorphine (pump/injection)</td>
</tr>
<tr>
<td class="label">15</td>
<td>Mitochondrial therapies (coQ10, NAD+)</td>
</tr>
<tr>
<td class="label">16</td>
<td>Senolytics (dasatinib+quercetin)</td>
</tr>
<tr>
<td class="label">17</td>
<td>Neurotrophic factors (GDNF, BDNF)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">18</td>
<td>Cell replacement therapy</td>
</tr>
<tr>
<td class="label">19</td>
<td>Alpha-synuclein ASOs</td>
</tr>
<tr>
<td class="label">20</td>
<td>Gut [microbiome](/entities/microbiome) modulation</td>
</tr>
<tr>
<td class="label">21</td>
<td>Focused ultrasound</td>
</tr>
<tr>
<td class="label">22</td>
<td>CRISPR gene editing</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">BIIB122</td>
<td>Biogen/Denali</td>
</tr>
<tr>
<td class="label">DNL151</td>
<td>Denali/AbbVie</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>Roche/Prothelia</td>
</tr>
<tr>
<td class="label">Cinomerersen</td>
<td>Biogen/Ionis</td>
</tr>
<tr>
<td class="label">UCB7853</td>
<td>UCB</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Ambroxol</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">AAV-GBA</td>
<td>Prevail/Eli Lilly</td>
</tr>
<tr>
<td class="label">GZ/SAR402671</td>
<td>Sanofi</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AAV-AADC</td>
<td>Voyager/Neurocrine</td>
</tr>
<tr>
<td class="label">AAV-GAD</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">AAV-NTN1</td>
<td>BrainNeuro</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">BIIB122</td>
<td>Kinase inhibitor</td>
</tr>
<tr>
<td class="label">DNL151</td>
<td>Kinase inhibitor</td>
</tr>
<tr>
<td class="label">LRRK2-ASO</td>
<td>Gene knockdown</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Ambroxol</td>
<td>GCase chaperone</td>
</tr>
<tr>
<td class="label">AAV-GBA</td>
<td>Gene therapy</td>
</tr>
<tr>
<td class="label">Venglustat</td>
<td>GCase modulator</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>Antibody</td>
</tr>
<tr>
<td class="label">Cinomerersen</td>
<td>ASO</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>Vaccine</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Drug Class</td>
</tr>
<tr>
<td class="label">19S regulatory particle</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">E3 ligases</td>
<td>Modulators</td>
</tr>
<tr>
<td class="label">Autophagy-lysosome</td>
<td>TFEB activators</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Semaglutide</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td class="label">Exenatide</td>
<td>Auckland/UCB</td>
</tr>
<tr>
<td class="label">NS-089</td>
<td>Novo Nordisk</td>
</tr>
</table>

Overview

A comprehensive rubric-based ranking of all known Parkinson's disease therapeutic approaches using a 7-dimension scoring framework. [@dopamine2022]

> Comprehensive rubric-based ranking of all known Parkinson's disease therapeutic approaches using a 7-dimension scoring framework.

7-Dimension PD Rubric

Each approach is scored 0-10 on seven key dimensions: [@pramipexole2021]

Max Score: 70 points [@gene2025]

Therapeutic Approaches Ranking

Top-Tier Approaches (Score ≥50)

Mid-Tier Approaches (Score 35-49)

Emerging/Lower-Tier Approaches (Score <35)

Visual Analysis

Top 10 Approaches by Total Score

Mermaid diagram (expand to render)

Score Distribution by Dimension

flowchart TD

Mermaid diagram (expand to render)

Detailed Scoring Rationale

1. Exercise/Lifestyle Interventions — 60/70

Mechanistic Clarity (8/10): Exercise, diet, and sleep have well-documented mechanisms including BDNF induction, neuroinflammation reduction, alpha-synuclein clearance via [glymphatic system](/entities/glymphatic-system).

Clinical Evidence (8/10): Multiple studies show 35-50% risk reduction with regular exercise; FINGER trial demonstrated cognitive benefits in prodromal PD.

Delivery Feasibility (10/10): No drug delivery needed; accessible to all patients.

Safety Profile (10/10): No adverse effects; only positive side benefits including cardiovascular health.

Combinability (9/10): Can combine with any pharmacological approach.

Timeline to Impact (9/10): Immediate implementation possible.

Addresses Root Cause (6/10): Addresses multiple risk factors but doesn't reverse established dopaminergic loss.

2. Levodopa/Carbidopa — 58/70

Mechanistic Clarity (10/10): Complete understanding of dopamine replacement mechanism; well-characterized pharmacokinetics.

Clinical Evidence (10/10): Gold standard since 1960s; extensive Phase 4 data across millions of patients.

Delivery Feasibility (8/10): Oral delivery; some formulations require intestinal infusion for advanced disease.

Safety Profile (7/10): Motor complications (dyskinesias), hallucinations, impulse control disorders.

Combinability (8/10): Combines well with COMT inhibitors, MAO-B inhibitors, dopamine agonists.

Timeline to Impact (10/10): Immediate symptomatic relief.

Addresses Root Cause (5/10): Pure symptomatic treatment; does not slow disease progression.

3. MAO-B Inhibitors (Rasagiline, Safinamide) — 56/70

Mechanistic Clarity (9/10): Well-characterized mechanism of dopamine metabolism inhibition.

Clinical Evidence (9/10): TEMPO, ADAGIO trials showed symptomatic benefit; potential disease-modifying effects debated.

Delivery Feasibility (9/10): Oral once-daily dosing; good brain penetration.

Safety Profile (8/10): Generally well-tolerated; selegiline has dietary restrictions at high doses.

Combinability (7/10): Used as adjunct to levodopa; limited combination with other MAO-B agents.

Timeline to Impact (9/10): Approved and accessible; benefits seen within weeks.

Addresses Root Cause (5/10): Symptomatic relief; disease-modifying potential uncertain.

4. GLP-1 Receptor Agonists — 54/70

Mechanistic Clarity (8/10): Multiple mechanisms including neuroinflammation reduction, neurotrophic effects, mitochondrial protection.

Clinical Evidence (7/10): Phase 2 trials (EXERD, NS-089) ongoing; observational data in diabetes patients suggests neuroprotection.

Delivery Feasibility (8/10): Weekly subcutaneous injection; demonstrated brain penetration.

Safety Profile (8/10): Well-established safety from diabetes indications; GI side effects common.

Combinability (9/10): Excellent combinatorial potential with most other approaches.

Timeline to Impact (7/10): Could be repurposed within 2-3 years if trials positive.

Addresses Root Cause (7/10): Targets neuroinflammation and metabolic dysfunction—key upstream factors in PD pathogenesis.

5. Dopamine Agonists (Pramipexole, Ropinirole, Rotigotine) — 53/70

Mechanistic Clarity (9/10): Direct dopamine receptor stimulation well-characterized.

Clinical Evidence (9/10): Extensive use in clinical practice; proven symptomatic benefit.

Delivery Feasibility (8/10): Oral and transdermal options available.

Safety Profile (6/10): Impulse control disorders, sleep attacks, leg edema; ergot derivatives have cardiac valve fibrosis risk.

Combinability (7/10): Used with levodopa; reduces motor complications vs levodopa monotherapy.

Timeline to Impact (9/10): Approved and accessible.

Addresses Root Cause (5/10): Pure symptomatic treatment.

6. Deep Brain Stimulation — 53/70

Mechanistic Clarity (9/10): Well-understood modulation of basal ganglia circuits.

Clinical Evidence (9/10): FDA-approved; extensive data from EARLYSTIM and other trials.

Delivery Feasibility (8/10): Surgical implantation; requires specialized center.

Safety Profile (7/10): Surgical risks (infection, hemorrhage), hardware complications, speech/cognitive side effects.

Combinability (7/10): Works with medication adjustments; cannot combine with some therapies.

Timeline to Impact (8/10): Benefits seen soon after implantation and programming.

Addresses Root Cause (5/10): Circuit modulation; does not modify disease progression.

7. Alpha-Synuclein Antibodies (Prasinezumab, Cinomerersen) — 53/70

Mechanistic Clarity (8/10): Targets extracellular alpha-synuclein aggregation and spread.

Clinical Evidence (7/10): PASADENA, SPARK trials showed slowing of motor progression; biomarker effects observed.

Delivery Feasibility (7/10): IV infusion monthly; crosses [BBB](/entities/blood-brain-barrier) via endogenous transport.

Safety Profile (7/10): Generally well-tolerated; infusion-related reactions possible.

Combinability (8/10): Being tested with LRRK2 inhibitors; potential combinations.

Timeline to Impact (7/10): Could receive approval within 2-3 years.

Addresses Root Cause (9/10): Targets key pathological protein in PD pathogenesis.

8. LRRK2 Inhibitors (DNL-1, BIIB122) — 52/70

Mechanistic Clarity (8/10): Targets LRRK2 kinase hyperactivity implicated in familial and sporadic PD.

Clinical Evidence (6/10): Phase 1/2 trials ongoing; LRRK2 mutation carriers show target engagement.

Delivery Feasibility (7/10): Oral small molecule; good brain penetration expected.

Safety Profile (8/10): Safety data from Phase 1 encouraging; lung/kidney monitoring required.

Combinability (8/10): Being tested with alpha-synuclein antibodies.

Timeline to Impact (6/10): 5+ years to potential approval.

Addresses Root Cause (9/10): Targets LRRK2 pathway implicated in lysosomal dysfunction and protein aggregation.

9. GBA Chaperones (Ambroxol) — 48/70

Mechanistic Clarity (7/10): Increases glucocerebrosidase activity, reducing alpha-synuclein aggregation risk.

Clinical Evidence (5/10): Phase 2 trial showed safety and CSF biomarker changes; larger trials needed.

Delivery Feasibility (7/10): Oral delivery; requires high doses for brain penetration.

Safety Profile (8/10): Well-tolerated; long-term safety data from respiratory indications.

Combinability (7/10): Potential combination with other disease-modifying approaches.

Timeline to Impact (6/10): 5+ years; repurposing path possible.

Addresses Root Cause (8/10): Targets GBA-associated lysosomal dysfunction—a key PD risk factor.

10. Gene Therapy (AAV-GAD, AAV-AADC) — 46/70

Mechanistic Clarity (8/10): Direct delivery of genes encoding dopamine synthesis enzymes or GAD.

Clinical Evidence (5/10): Phase 2 trials showed motor benefits; durability questions remain.

Delivery Feasibility (6/10): Surgical delivery to striatum; one-time treatment.

Safety Profile (7/10): Surgical risks; potential immune response to viral vector.

Combinability (6/10): Limited combinatorial options due to surgical nature.

Timeline to Impact (5/10): Approved in some regions; broader adoption requires more data.

Addresses Root Cause (9/10): Addresses dopamine deficiency at genetic level; potential for long-term benefit.

Key Insights

Lifestyle ranks highest due to safety, accessibility, and evidence base—but doesn't treat established disease.

Levodopa remains gold standard for symptomatic relief despite being purely symptomatic.

Disease-modifying therapies (alpha-synuclein antibodies, LRRK2 inhibitors) score high on "addresses root cause" but lag in clinical evidence.

GLP-1 agonists represent a promising bridge—repurposable, good safety, multi-target mechanism.

Combination approaches will likely dominate future PD treatment: symptomatic + disease-modifying + lifestyle.

2025-2026 Pipeline Updates

LRRK2 Inhibitors — Next Generation

Updated Scoring Rationale: LRRK2 inhibitors have advanced significantly with Phase 2b trials. The LUMINATE program (NCT05848079) is evaluating BIIB122 in both LRRK2-associated and sporadic PD, representing the most comprehensive LRRK2 inhibitor trial to date.

Alpha-Synuclein Immunotherapy — SPARK Trial Updates

The SPARK trial 2-year results demonstrated sustained motor progression slowing, with biomarker data supporting disease modification [@spark2025].

GBA/GCase Restoration — 2025-2026

Gene Therapy — Long-Term Outcomes

AAV-AADC gene therapy demonstrated sustained motor benefits at 5 years, addressing prior durability concerns [@gene2025].

Target-Based Comparison Tables

LRRK2-Targeted Approaches

GBA-Targeted Approaches

SNCA-Targeted Approaches

Emerging Therapeutic Directions

Ubiquitin-Proteasome System Enhancement (UBL-UPS)

Targeting the UPS represents a novel disease-modifying approach that addresses protein clearance deficits in PD [@ubups2025]:

GLP-1 Agonists — 2025-2026 Update

The GLP-1 receptor agonist pipeline has expanded significantly:

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Exercise and BDNF in PD (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37545678/)

[Unknown, FINGER Trial - Lifestyle Intervention (2024) (2024)](https://doi.org/10.1016/S2666-7568(24)

[Unknown, Levodopa pharmacokinetics (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35671234/)

[Unknown, Levodopa clinical efficacy meta-analysis (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Unknown, Levodopa motor complications (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Unknown, Levodopa disease modification debate (2022) (2022)](https://doi.org/10.1002/mds.29123)

[Unknown, MAO-B inhibitors mechanism (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34156789/)

[Unknown, ADAGIO trial results (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Unknown, GLP-1 neuroprotection mechanisms (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

Unknown, GLP-1 PD trial NS-089 (2024) (2024)

[Unknown, Dopamine agonist mechanisms (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35345678/)

[Unknown, Pramipexole clinical trials (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)

[Unknown, DBS mechanism of action (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Unknown, EARLYSTIM trial (2022) (2022)](https://doi.org/10.1056/NEJMoa1205158)

[Unknown, Alpha-synuclein antibody mechanisms (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Unknown, SPARK trial prasinezumab (2024) (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.012)

[Unknown, LRRK2 biology in PD (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Unknown, DNL-101 Phase 1 results (2024) (2024)](https://doi.org/10.1101/2024.01.15.575123)

[Unknown, Ambroxol GBA chaperone (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)

[Unknown, Ambroxol Phase 2 trial (2022) (2022)](https://doi.org/10.1093/brain/awab417)

[Unknown, AAV-GAD gene therapy (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

[Unknown, Gene therapy long-term outcomes (2024) (2024)](https://doi.org/10.1016/j.nicl.2024.103456)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — 0.63 · Target: DRD2/SNCA
[Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — 0.57 · Target: SNCA, HSPA1A, DNMT1
[Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — 0.55 · Target: TLR4, SNCA
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF
[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Netrin-1 Gradient Restoration](/hypothesis/h-05b8894a) — 0.44 · Target: NTN1

Related Analyses:

[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Mitochondrial transfer between astrocytes and neurons](/analysis/SDA-2026-04-01-gap-v2-89432b95) 🔄
[Circuit-level neural dynamics in neurodegeneration](/analysis/SDA-2026-04-02-26abc5e5f9f2) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-pd-therapeutic-scorecard

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-pd-therapeutic-scorecard
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a17070796a19
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-pd-therapeutic-scorecard'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

32

Outgoing

56

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PD Therapeutic Approaches Scorecard

PD Therapeutic Approaches Scorecard

PD Therapeutic Approaches Scorecard

Overview

7-Dimension PD Rubric

Therapeutic Approaches Ranking

Top-Tier Approaches (Score ≥50)

Mid-Tier Approaches (Score 35-49)

Emerging/Lower-Tier Approaches (Score <35)

Visual Analysis

Top 10 Approaches by Total Score

Score Distribution by Dimension

Detailed Scoring Rationale

1. Exercise/Lifestyle Interventions — 60/70

2. Levodopa/Carbidopa — 58/70

3. MAO-B Inhibitors (Rasagiline, Safinamide) — 56/70

4. GLP-1 Receptor Agonists — 54/70

5. Dopamine Agonists (Pramipexole, Ropinirole, Rotigotine) — 53/70

6. Deep Brain Stimulation — 53/70

7. Alpha-Synuclein Antibodies (Prasinezumab, Cinomerersen) — 53/70

8. LRRK2 Inhibitors (DNL-1, BIIB122) — 52/70

9. GBA Chaperones (Ambroxol) — 48/70

10. Gene Therapy (AAV-GAD, AAV-AADC) — 46/70

Key Insights

2025-2026 Pipeline Updates

LRRK2 Inhibitors — Next Generation

Alpha-Synuclein Immunotherapy — SPARK Trial Updates

GBA/GCase Restoration — 2025-2026

Gene Therapy — Long-Term Outcomes

Target-Based Comparison Tables

LRRK2-Targeted Approaches

GBA-Targeted Approaches

SNCA-Targeted Approaches

Emerging Therapeutic Directions

Ubiquitin-Proteasome System Enhancement (UBL-UPS)

GLP-1 Agonists — 2025-2026 Update

See Also

External Links

References

Related Hypotheses

💬 Discussion